Annals of Hematology

, Volume 84, Issue 6, pp 406–408 | Cite as

Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARα acute promyelocytic leukemia (APML)

  • B. George
  • B. Poonkuzhali
  • V. M. Srivastava
  • M. Chandy
  • A. Srivastava
Letter to the Editor


Patients with acute promyelocytic leukemia (APML) with the t(11;17) translocation usually respond poorly to all-trans retinoic acid (ATRA) and chemotherapy. We describe a patient with promyelocytic leukemia zinc finger/retinoic acid receptor alpha (PLZF/RARα) APML who was treated with combination chemotherapy after poor response to arsenic trioxide. He achieved hematological remission in 4 weeks followed by achievement of molecular remission in 8 weeks. Four cycles of consolidation chemotherapy followed by four cycles of maintenance therapy were given over a period of 9 months. At a follow-up of 32 months after achieving hematological remission, he continues to remain in hematological and molecular remission with normal blood parameters and negative reverse transcriptase polymerase chain reaction (RT-PCR) results. Combination chemotherapy can achieve sustained remission in patients with PLZF/RARα APML.


PLZF/RARα APML Chemotherapy Molecular remission 


  1. 1.
    Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, Waxman S, Zelent A (1993) Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukemia. EMBO J 12:1161–1167PubMedGoogle Scholar
  2. 2.
    Licht D, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBalsio A, Miller WH Jr (1995) Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85:1083–1094PubMedGoogle Scholar
  3. 3.
    Guidez F, Huang W, Tong JH et al (1994) Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient. Leukemia 8:312PubMedGoogle Scholar
  4. 4.
    Petti MC, Fazi F, Gentile M, Diverio D, De Fabritis P, De Propis MS, Fiorini R, Spiriti MA, Padula F (2002) Complete remission through blast cell differentiation in PLZF/RAR alpha positive acute promyelocytic leukemia. Blood 100:1065–1067CrossRefPubMedGoogle Scholar
  5. 5.
    Jansen JH, de Ridder MC, Geertsma W, Erpelinck CA, van Lom K, Smit EM, Slater R, van der Reijden BA, de Greef GE, Sonneveld P, Lowenberg B (1999) Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 94:39–45PubMedGoogle Scholar
  6. 6.
    Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, Walker H, Culligan D, Waters J, Pomfret M, Goldstone A, Burnett A, Freemont P, Sheer D, Solomon E (1997) Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 90:4876–4885PubMedGoogle Scholar
  7. 7.
    Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896–903CrossRefPubMedGoogle Scholar
  8. 8.
    Licht JD, Chomienne C, Goy A, Chen A, Scott AA (1995) Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85:1083–1094PubMedGoogle Scholar
  9. 9.
    Culligan DJ, Stevenson D, Chee YL, Grimwade D (1998) Acute promyelocytic leukemia with t(11;17)(q23;q12–21) and a good initial response to prolonged ATRA and combination chemotherapy. Br J Haematol 100:328–330CrossRefPubMedGoogle Scholar
  10. 10.
    Jansen JH, Lowenberg B (2001) Acute promyelocytic leukemia with a PLZF-RAR alpha fusion protein. Semin Hematol 38:37–41CrossRefGoogle Scholar
  11. 11.
    Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, Minard P, Degos L, Varet B, de The H (1999) Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene 18:1113–1118CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • B. George
    • 1
  • B. Poonkuzhali
    • 1
  • V. M. Srivastava
    • 1
  • M. Chandy
    • 1
  • A. Srivastava
    • 1
  1. 1.Department of HaematologyChristian Medical College and HospitalVelloreIndia

Personalised recommendations